BioSpace News Archive

Memorial Hospital at Gulfport will begin offering specialty pharmacy services, fall 2019, to enhance care for patients who require complex and expensive medications.

Lineage Cell Therapeutics, Inc. announced that it will report its third quarter 2019 financial and operating results on Tuesday, November 12, 2019, following the close of the U.S. financial markets.

Results of a nationwide survey indicate most hospitals do not employ best practices in glucose control, which leads to increased safety risks, higher readmission rates and significantly greater costs.

IVERIC bio, Inc. reported that on November 1, 2019, the Company granted Dr. Abraham Scaria a non-statutory stock option to purchase 300,000 shares of the Company’s common stock.

Research, interactive features and charitable opportunity support advancement of care

Silverback Therapeutics, Inc., a biopharmaceutical company developing a pipeline of systemically delivered, locally active therapies, will present preclinical data on its lead candidate, SBT6050, at the Society for Immunotherapy of Cancer 34th Annual Meeting taking place November 6-10, 2019 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

BeiGene and Seattle Genetics to Collaborate on Global Clinical Trials

Robust survivin-specific T cell responses observed in recurrent late-stage ovarian cancer in nearly all evaluable subjects

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that the company will host a conference call and live webcast on Tuesday, November 12, 2019 at 5:00 p.m. EST to report third quarter 2019 financial results and discuss recent business highlights.

Data support potential clinical use as a cancer immunotherapy treatment in various combinations with COM701 and PD-1 inhibitors